Rhenium labeled McAb-SZ39 and colloid

ZU Jianhua，

DONG Mo，

LI Huiyuan，

WU Yuanfang

Nuclear Science and Techniques

Vol.10, No.4

pp.197-202

Published in print 01 Nov 1999

155400

Two kinds of rhenium labeled radiopharmaceuticals for therapy of the human brain glioma were prepared. Anti-human brain glioma monoclonal antibody (McAb-SZ39) was directly labeled with $^{186} Re O_{4}^{-}$ . When ascorbic acid was used as reduction agent of antibody and the reduction of $^{186} Re O_{4}^{-}$ was finished in sodium gluconate solution (pH=2.54), the labeling efficiency was 96.2%. After purification, the labeled products were tested in respect of immunoreactivity, in vitro stability as well as inhibitory efficiency against human glioma transplanted in nude mice. $^{188} Re O_{4}^{-}$ labeled colloid was synthesized by using a two-step method. The size of radiocolloid particles was around 2~5μm, and the radiochemical yield was over 95%. Nude mice Experiments demonstrated that the inhibitory efficiency against human brain glioma of ¹⁸⁸Re-colloid and ¹⁸⁸Re-McAb-SZ39 was 90% and 65%, respectively.

Radiopharmaceuticals186ReO4−188ReO4−LabelMcAb-SZ39Colloid

References

Zhu J H, Du Z W, Huang Q et al. J Suzhou Med Col (in Chinese), 1988, 8: 276~281

Pressman D, Keighley G. J Immunol, 1948, 59: 141~146

Goldrosen M H, Vanderheyden J L. Fritzberg A R et al. Cancer Res, 1990, 50: 7973~7978

Vanderheyden J L, Gofinch S. Srinivasan A et al. J Nucl Med, 1989. 30: 793~798

John E, Thakur M J, Defulvio M R et al. J Nucl Med. 1993, 34: 260~267

Griffiths G L. Gddenberg D M. Hansen H J et al. Cancer Res, 1994, 73: 767~768

Wang S J, Lin W Y, Hereh B T et al. Eur J Nucl Med, 1995, 22: 505~507

Liu Z L, Luo S Z, Dai T E. Isotope (in Chnese), 1995, 8: 65~70